Robert Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day: Dara-CyBorD induction shows better outcomes vs. CyBorD for transplant-ineligible myeloma patients (median PFS 25.8 vs 16.8 mos.; ORR 86% vs 65%; VGPR 52% vs 28%).
However, data look worse than even just Rd in MAIA (34.4 month PFS).”
Source: Robert Orlowski/X
Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma
Authors: Peter Mollee, John Reynolds, Wojt Janowski, Hang Quach, Philip Campbell, Simon Gibbs, Sophie Lee, Edwin Lee, Kerry Taylor, Tara Cochrane, Craig Wallington-Gates, Fiona Kwok, Nicholas Weber, Ian Kerridge, Helen Weston, P. Joy Ho, Michael F Leahy, Noemi Horvath, and Andrew Spencer.
Other insights by Robert Orlowski on OncoDaily.